scispace - formally typeset
Search or ask a question
Author

M. Serra Mitjans

Bio: M. Serra Mitjans is an academic researcher. The author has contributed to research in topics: Lung cancer staging & Lung cancer. The author has an hindex of 2, co-authored 2 publications receiving 1967 citations.

Papers
More filters
Journal ArticleDOI
Peter Goldstraw1, Kari Chansky, John Crowley, Ramón Rami-Porta2, Hisao Asamura3, Wilfried Ernst Erich Eberhardt4, Andrew G. Nicholson1, Patti A. Groome5, Alan Mitchell, Vanessa Bolejack, David Ball6, David G. Beer7, Ricardo Beyruti8, Frank C. Detterbeck9, Wilfried Eberhardt4, John G. Edwards10, Françoise Galateau-Salle11, Dorothy Giroux12, Fergus V. Gleeson13, James Huang14, Catherine Kennedy15, Jhingook Kim16, Young Tae Kim17, Laura Kingsbury12, Haruhiko Kondo18, Mark Krasnik19, Kaoru Kubota20, Antoon Lerut21, Gustavo Lyons, Mirella Marino, Edith M. Marom22, Jan P. van Meerbeeck23, Takashi Nakano24, Anna K. Nowak25, Michael D Peake26, Thomas W. Rice27, Kenneth E. Rosenzweig28, Enrico Ruffini29, Valerie W. Rusch14, Nagahiro Saijo, Paul Van Schil23, Jean-Paul Sculier30, Lynn Shemanski12, Kelly G. Stratton12, Kenji Suzuki31, Yuji Tachimori32, Charles F. Thomas33, William D. Travis14, Ming-Sound Tsao34, Andrew T. Turrisi35, Johan Vansteenkiste21, Hirokazu Watanabe, Yi-Long Wu, Paul Baas36, Jeremy J. Erasmus22, Seiki Hasegawa24, Kouki Inai37, Kemp H. Kernstine38, Hedy L. Kindler39, Lee M. Krug14, Kristiaan Nackaerts21, Harvey I. Pass40, David C. Rice22, Conrad Falkson5, Pier Luigi Filosso29, Giuseppe Giaccone41, Kazuya Kondo42, Marco Lucchi43, Meinoshin Okumura44, Eugene H. Blackstone27, F. Abad Cavaco, E. Ansótegui Barrera, J. Abal Arca, I. Parente Lamelas, A. Arnau Obrer45, R. Guijarro Jorge45, D. Ball6, G.K. Bascom46, A. I. Blanco Orozco, M. A. González Castro, M.G. Blum, D. Chimondeguy, V. Cvijanovic47, S. Defranchi48, B. de Olaiz Navarro, I. Escobar Campuzano2, I. Macía Vidueira2, E. Fernández Araujo49, F. Andreo García49, Kwun M. Fong, G. Francisco Corral, S. Cerezo González, J. Freixinet Gilart, L. García Arangüena, S. García Barajas50, P. Girard, Tuncay Göksel, M. T. González Budiño51, G. González Casaurrán50, J. A. Gullón Blanco, J. Hernández Hernández, H. Hernández Rodríguez, J. Herrero Collantes, M. Iglesias Heras, J. M. Izquierdo Elena, Erik Jakobsen, S. Kostas52, P. León Atance, A. Núñez Ares, M. Liao, M. Losanovscky, G. Lyons, R. Magaroles53, L. De Esteban Júlvez53, M. Mariñán Gorospe, Brian C. McCaughan15, Catherine J. Kennedy15, R. Melchor Íñiguez54, L. Miravet Sorribes, S. Naranjo Gozalo, C. Álvarez de Arriba, M. Núñez Delgado, J. Padilla Alarcón, J. C. Peñalver Cuesta, Jongsun Park16, H. Pass40, M. J. Pavón Fernández, Mara Rosenberg, Enrico Ruffini29, V. Rusch14, J. Sánchez de Cos Escuín, A. Saura Vinuesa, M. Serra Mitjans, Trond Eirik Strand, Dragan Subotic, S.G. Swisher22, Ricardo Mingarini Terra8, Charles R. Thomas33, Kurt G. Tournoy55, P. Van Schil23, M. Velasquez, Y.L. Wu, K. Yokoi 
Imperial College London1, University of Barcelona2, Keio University3, University of Duisburg-Essen4, Queen's University5, Peter MacCallum Cancer Centre6, University of Michigan7, University of São Paulo8, Yale University9, Northern General Hospital10, University of Caen Lower Normandy11, Fred Hutchinson Cancer Research Center12, University of Oxford13, Memorial Sloan Kettering Cancer Center14, University of Sydney15, Sungkyunkwan University16, Seoul National University17, Kyorin University18, University of Copenhagen19, Nippon Medical School20, Katholieke Universiteit Leuven21, University of Texas MD Anderson Cancer Center22, University of Antwerp23, Hyogo College of Medicine24, University of Western Australia25, Glenfield Hospital26, Cleveland Clinic27, Icahn School of Medicine at Mount Sinai28, University of Turin29, Université libre de Bruxelles30, Juntendo University31, National Cancer Research Institute32, Mayo Clinic33, University of Toronto34, Sinai Grace Hospital35, Netherlands Cancer Institute36, Hiroshima University37, City of Hope National Medical Center38, University of Chicago39, New York University40, Georgetown University41, University of Tokushima42, University of Pisa43, Osaka University44, University of Valencia45, Good Samaritan Hospital46, Military Medical Academy47, Fundación Favaloro48, Autonomous University of Barcelona49, Complutense University of Madrid50, University of Oviedo51, National and Kapodistrian University of Athens52, Rovira i Virgili University53, Autonomous University of Madrid54, Ghent University55
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.

2,826 citations

Journal ArticleDOI
TL;DR: An extensive analysis has produced stage classification proposals for lung cancer with a robust degree of discriminatory consistency and general applicability and external validation is encouraged to identify areas of strength and weakness.

182 citations


Cited by
More filters
Journal ArticleDOI
24 Jan 2018-Nature
TL;DR: Continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
Abstract: Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.

2,410 citations

Journal ArticleDOI
TL;DR: Prevention and early detection of lung cancer with an emphasis on lung cancer screening is discussed, and the importance of smoking prevention and cessation is acknowledged.

2,027 citations

Journal ArticleDOI
01 Aug 2019
TL;DR: The results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLCs.
Abstract: Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non-small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic.

993 citations

Journal ArticleDOI
01 Jan 2017-Chest
TL;DR: This paper summarizes the eighth edition of lung cancer stage classification, which is the worldwide standard as of January 1, 2017, based on a large global database, a sophisticated analysis, extensive internal validation as well as multiple assessments confirming generalizability.

987 citations